Compare EOLS & NAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOLS | NAN |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.3M | 356.7M |
| IPO Year | 2018 | N/A |
| Metric | EOLS | NAN |
|---|---|---|
| Price | $4.32 | $11.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | ★ 815.1K | 62.2K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.37% |
| EPS Growth | ★ 1.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $297,176,000.00 | N/A |
| Revenue This Year | $13.27 | N/A |
| Revenue Next Year | $17.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.61 | N/A |
| 52 Week Low | $3.86 | $10.79 |
| 52 Week High | $12.28 | $11.67 |
| Indicator | EOLS | NAN |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 58.80 |
| Support Level | $4.10 | $11.39 |
| Resistance Level | $4.99 | $11.61 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 58.71 | 96.15 |
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.